|
KMID : 1137020210320060090
|
|
Journal of Gynecologic Oncology
2021 Volume.32 No. 6 p.90 ~ p.90
|
|
|
Comparisons of survival outcomes between bevacizumab and olaparib in BRCA-mutated, platinum-sensitive relapsed ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3052)
|
|
Kim Se-Ik
Lee Jeong-Won
Kim Ki-Dong
Lee Maria
Yoo Ji-Geun
Choi Min-Chul
Hwangbo Su-Hyun
Kwak Young-Hwa
Lee Jong-Min
Shin So-Jin
Shim Seung-Hyuk
Kim Min-Kyu
|
|
|
Abstract
|
|
|
|
We conducted a matching study to compare survival between bevacizumab (BEV) and olaparib (OLA) in BRCA-mutated, platinum-sensitive relapsed high-grade serous ovarian carcinoma. OLA was superior to BEV in improving progression-free survival, but no difference in overall survival was observed. The use of OLA might be prioritized in this setting.
|
|
|
KEYWORD
|
|
|
Cystadenocarcinoma, Serous, Genes, BRCA1, Genes, BRCA2, Mutation
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
    
|